TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8752486

Group type: EXPERIMENTAL
Intervention: Adeno-tonsillectomy in children
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Uvulo-palato-pharyngoplasty, midline laser grossectomy, or nasal surgery in adults
Number of subjects: 149
Study: 2231833

Group type: EXPERIMENTAL
Intervention: 5 mg flumazenil (group 1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 1 mg flumazenil (group 2)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 5 mg flumazenil (group 3)
Number of subjects: 72

Group type: COMPARATOR
Intervention: 1 mg flumazenil (group 4)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: flumazenil (group 5)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 200 mg flumazenil
Number of subjects: 72
Study: 31696936

Group type: EXPERIMENTAL
Intervention: Core cooling by 1.0°C
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Core heating by 1.5°C
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acute hypoxia (PET,O2 = 50 mm Hg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Core cooling and heating after acclimatisation to 4330 m
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Reaction time with heating
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Reaction time with cooling
Number of subjects: 12
Study: 30554300

Group type: EXPERIMENTAL
Intervention: Memory practice condition
Number of subjects: 358

Group type: COMPARATOR
Intervention: Health education condition
Number of subjects: 358

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 358
Study: 28756115

Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus reuteri)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 30
Study: 26786311

Group type: EXPERIMENTAL
Intervention: Combination treatment (folic acid 2.5 mg/day, vitamin B6 50 mg/day, vitamin B12 1 mg/day)
Number of subjects: 3925

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3925
Study: 24163081

Group type: EXPERIMENTAL
Intervention: Localized P2 receptor blockade (pyridoxal‐5‐phosphate)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control trial (normal saline)
Number of subjects: 1
Study: 22699175

Group type: EXPERIMENTAL
Intervention: Self-management program (counseling-centered activities in small groups) for 6 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 61
Study: 19596954

Group type: EXPERIMENTAL
Intervention: Lentinan plus chemotherapy
Number of subjects: 650

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 650
Study: 17584429

Group type: EXPERIMENTAL
Intervention: Diet intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 15086284

Group type: EXPERIMENTAL
Intervention: 20 mg of enoxaparin administered subcutaneously once daily for 10 (+/‐4) days
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: 40 mg of enoxaparin administered subcutaneously once daily for 10 (+/‐4) days
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo administered subcutaneously once daily for 10 (+/‐4) days
Number of subjects: 224
Study: 12204931

Group type: EXPERIMENTAL
Intervention: Psychological treatment (graded exercise)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Self-help group membership
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sickness benefit receipt
Number of subjects: 114

Group type: COMPARATOR
Intervention: Dysphoria (Hospital Anxiety and Depression scale)
Number of subjects: 114
Study: 9842172

Group type: EXPERIMENTAL
Intervention: Family-centered postpartum care (FCPPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional postpartum care (TPPC)
Number of subjects: 0
Study: 8082374

Group type: EXPERIMENTAL
Intervention: Room temperature injectate using an external thermistor
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Room temperature injectate using an internal RA thermistor
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Iced injectate using an external thermistor
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Iced injectate using an internal RA thermistor
Number of subjects: 20
Study: 2698591

Group type: EXPERIMENTAL
Intervention: Induction of labor by stripping of membranes and i.v. oxytocin infusion, with artificial rupture of membranes when the cervical opening was 3 cm or more in diameter.
Number of subjects: 188

Group type: COMPARATOR
Intervention: Close monitoring without induction except when indicated for medical reasons.
Number of subjects: 188
Study: 338079

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (10 g during the first 2 1/2 days)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 482
Study: 31294648

Group type: EXPERIMENTAL
Intervention: Observed condition (participants told they were being evaluated)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unobserved condition (participants performed tasks with no mention of observation or evaluation)
Number of subjects: 0
Study: 31551192

Group type: EXPERIMENTAL
Intervention: CircRNA expression in vaginal epithelial tissue from women with LDs
Number of subjects: 2

Group type: COMPARATOR
Intervention: CircRNA expression in vaginal epithelial tissue from normal control groups
Number of subjects: 2
Study: 27745812

Group type: EXPERIMENTAL
Intervention: bivalent rLP2086 (120 μg)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 25996793

Group type: EXPERIMENTAL
Intervention: Propofol-ketamine (PK)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Propofol-fentanyl (PF)
Number of subjects: 92
Study: 22801243

Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin (G-GR) 1800 mg
Number of subjects: 452

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study: 21300305

Group type: EXPERIMENTAL
Intervention: Automated Home Monitoring (AHM)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Standard-Care Group (NAHM)
Number of subjects: 188
Study: 18308500

Group type: EXPERIMENTAL
Intervention: Tailored print intervention
Number of subjects: 140

Group type: COMPARATOR
Intervention: Nontailored print intervention
Number of subjects: 140
Study: 16053850

Group type: EXPERIMENTAL
Intervention: Clonidine (15 microg/ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Epinephrine (12.5 microg/ml)
Number of subjects: 40
Study: 11943931

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no thalidomide)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: APC resistance (regardless of thalidomide)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Thalidomide with APC resistance
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Normal APC response without thalidomide
Number of subjects: 62
Study: 10065788

Group type: EXPERIMENTAL
Intervention: MH61 monoclonal antibody
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Two-color fluorescence staining with FITC-PSA and anti-CD46 monoclonal antibody
Number of subjects: 39
Study: 8543350

Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 388

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 388
Study: 2207824

Group type: EXPERIMENTAL
Intervention: Propofol (1.2 mg/kg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Etomidate (0.2 mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both agents
Number of subjects: 28
Study: 6108729

Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 0
Study: 29121415

Group type: EXPERIMENTAL
Intervention: Trametinib 2 mg once daily until progressive disease, death, or unacceptable toxicity
Number of subjects: 20
Study: 27652249

Group type: EXPERIMENTAL
Intervention: PRF with DBM
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PRF alone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 36
Study: 24975110

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention with a telephone booster after 6 weeks and a manual-guided intervention for caregivers
Number of subjects: 312

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 312
Study: 23536942

Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg/day for 4 weeks, then randomized to 125 mg/day (Group 1) or 250 mg/day (Group 2) for 12 weeks.
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg/day (Group 1)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Bosentan 250 mg/day (Group 2)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Bosentan (both groups)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Bosentan (Group 2)
Number of subjects: 35
Study: 20967979

Group type: EXPERIMENTAL
Intervention: Local antibacterial treatment consisting of bladder ionophoresis, vaginal exposure to estrogens, and vibromagnetic action of RECTOMASSAGER attachment and AMUS‐01‐INTRAMAG device
Number of subjects: 68

Group type: COMPARATOR
Intervention: Systemic treatment
Number of subjects: 68
Study: 18687385

Group type: EXPERIMENTAL
Intervention: Valproate monotherapy for 6 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10
Study: 16184836

Group type: EXPERIMENTAL
Intervention: Behcet's disease patients
Number of subjects: 12
Study: 12526235

Group type: EXPERIMENTAL
Intervention: Tracheal gas insufflation (flow rate 6 L/min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No flow (control)
Number of subjects: 14
Study: 11090767

Group type: EXPERIMENTAL
Intervention: Low stimulation intensity (3x perception threshold)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High stimulation intensity (1.5x pain threshold)
Number of subjects: 14
Study: 9221412

Group type: EXPERIMENTAL
Intervention: 3D time of flight (TOF) MRA
Number of subjects: 54

Group type: COMPARATOR
Intervention: 3D phase contrast (PC) MRA
Number of subjects: 54
Study: 8102428

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.4 mg/kg every 12 h for 2 days)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 115
Study: 3463350

Group type: EXPERIMENTAL
Intervention: Goal of Abstinence (AB)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Controlled Drinking (CD)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lighter clients (AB vs CD)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Heavier clients (CD)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: First 3 weeks of treatment (abstinent or not)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Remaining 3 weeks of treatment (moderate drinker or not)
Number of subjects: 70
Study: 31982585

Group type: EXPERIMENTAL
Intervention: Educational video group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional residency training group
Number of subjects: 24
Study: 29379278

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection (7 mL PRP solution)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Prolotherapy (PRL) injection (7 mL 25% dextrose)
Number of subjects: 42
Study: 27893109

Group type: EXPERIMENTAL
Intervention: SYL1001 1.125% once daily
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 24623027

Group type: COMPARATOR
Intervention: Diabetes Education treatment
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Individualized coping skills education
Number of subjects: 226
Study: 22555622

Group type: EXPERIMENTAL
Intervention: Venlafaxine (75 mg per day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 19729266

Group type: EXPERIMENTAL
Intervention: Telephone continuing care (TCC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone continuing care (TCC) among lower severity (LS) participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual continuing care (UCC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual continuing care (UCC) among lower severity (LS) participants
Number of subjects: 0
Study: 18567918

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily for 14 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 16266356

Group type: EXPERIMENTAL
Intervention: Oxymorphone ER 40 mg
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Oxymorphone ER 20 mg
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Oxymorphone ER 20 mg and 40 mg
Number of subjects: 491

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491
Study: 12087719

Group type: EXPERIMENTAL
Intervention: Glutoxim
Number of subjects: 42
Study: 10795950

Group type: EXPERIMENTAL
Intervention: Low-magnitude behavioral incentives ($5/day vouchers for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no incentives)
Number of subjects: 0
Study: 8871884

Group type: EXPERIMENTAL
Intervention: Famciclovir (10 day course, oral)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1373429

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by radiotherapy (2 cycles)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Chemotherapy with radiosensitizing agent (3 cycles)
Number of subjects: 114
Study: 4063689

Group type: EXPERIMENTAL
Intervention: E‐Z‐CAT (barium sulphate)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Diatrizoate (Gastrografin)
Number of subjects: 111
Study: 29395372

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (whey protein, vitamin D, and E)
Number of subjects: 60
Study: 29903551

Group type: EXPERIMENTAL
Intervention: Metabolically adaptive chemoradiation (85 Gy in 30 fractions)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional chemoradiation treatment (60 Gy in 30 fractions)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Metabolically adaptive chemoradiation
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional chemoradiation
Number of subjects: 78
Study: 27776036

Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy (VL)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 19
Study: 24025633

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (9.7 to 10.7 mg/d)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group (placebo, 1.3 to 1.4 mg/d)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 193
Study: 20080256

Group type: EXPERIMENTAL
Intervention: Continuous wound infusion of bupivacaine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 70
Study: 19751371

Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg twice daily
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg once daily
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 16895945

Group type: EXPERIMENTAL
Intervention: Immediate computed tomography
Number of subjects: 2602

Group type: COMPARATOR
Intervention: Admission for observation
Number of subjects: 2602
Study: 15125339

Group type: EXPERIMENTAL
Intervention: Holdex de Vacuette (H)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Vacutainer (V)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Syringe (J)
Number of subjects: 512

Group type: COMPARATOR
Intervention: All samples analyzed
Number of subjects: 512
Study: 11439207

Group type: EXPERIMENTAL
Intervention: CHART (continuous hyperfractionated accelerated radiotherapy)
Number of subjects: 918

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: CHART
Number of subjects: 918
Study: 9383928

Group type: EXPERIMENTAL
Intervention: Home intervention (home visits from a lay home visitor for 1 year)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard services in a multidisciplinary growth and nutrition clinic (control group)
Number of subjects: 0
Study: 7524908

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (Ig) at a dose of 500 mg/kg every 2 weeks for the first 100 days post-BMT
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Detection of anti-HCV antibodies
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Routine screening of donors with sensitive tests
Number of subjects: 11
Study: 3365327

Group type: EXPERIMENTAL
Intervention: Deceptive administration of placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double-blind administration of placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo effects on motor performance
Number of subjects: 0
Study: 29618329

Group type: EXPERIMENTAL
Intervention: Digital exercise prescription tool with standard lifestyle consultation for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard usual-cardio-care lifestyle counselling for 3 months
Number of subjects: 0
Study: 26706398

Group type: EXPERIMENTAL
Intervention: SEAD program (2-week curriculum with operating room observerships, simulation workshops, and career discussions)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (reading the program's instructional manual)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Both groups (SEAD and control)
Number of subjects: 36
Study: 26670153

Group type: EXPERIMENTAL
Intervention: More behaviours for escaping from a house fire group
Number of subjects: 1112

Group type: COMPARATOR
Intervention: Fewer behaviours for escaping from a house fire group
Number of subjects: 1112
Study: 22960153

Group type: EXPERIMENTAL
Intervention: Gaze-contingent motor control
Number of subjects: 21

Group type: COMPARATOR
Intervention: Free-hand motor control
Number of subjects: 21
Study: 20639738

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg + TENS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg + TENS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pregabalin 300 mg + TENS placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pregabalin 600 mg + TENS placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study: 18615004

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 5895

Group type: EXPERIMENTAL
Intervention: verapamil SR
Number of subjects: 5895
Study: 20806385

Group type: EXPERIMENTAL
Intervention: Non-ablative 1,550 nm fractional laser therapy (FLT) - 4-5 sessions at 15 mJ/microbeam, 14-20% coverage
Number of subjects: 29

Group type: COMPARATOR
Intervention: Triple topical therapy (TTT) - hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% cream, applied once daily for 15 weeks
Number of subjects: 29
Study: 15542574

Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (end‐tidal Po(2) = 50 Torr) for 25 min (Study A)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (end‐tidal Po(2) = 50 Torr) for 105 min (Study B)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Isocapnic euoxia (end‐tidal Po(2) = 100 Torr) for 5 min (Study A)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Isocapnic euoxia (end‐tidal Po(2) = 100 Torr) for 10 min (Study B)
Number of subjects: 19
Study: 12187632

Group type: EXPERIMENTAL
Intervention: Metropolitan Primary Angioplasty Registry
Number of subjects: 0
Study: 9832694

Group type: EXPERIMENTAL
Intervention: Radial artery grafts
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Early parietal irregularities
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Serotonin challenge
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Calcium-channel antagonists therapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Preoperative severity of target-vessel stenosis
Number of subjects: 68
Study: 7975696

Group type: EXPERIMENTAL
Intervention: Anterior lesser curve seromyotomy with posterior truncal vagotomy (ASPTV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 100
Study: 2730323

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for one day (n = 23)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for four days (n = 27)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for four days (n = 14)
Number of subjects: 64
Study: 12219850

Group type: EXPERIMENTAL
Intervention: Participants with strong merit endorsement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants with preexisting perceptions of workplace discrimination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimentally induced perceptions of discrimination
Number of subjects: 0
Study: 31636172

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 2658

Group type: EXPERIMENTAL
Intervention: Metformin intervention
Number of subjects: 2658

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2658

Group type: COMPARATOR
Intervention: Metformin or placebo
Number of subjects: 2658
Study: 29789414

Group type: EXPERIMENTAL
Intervention: Personalized fitting device using 3D scanning solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no fitting device)
Number of subjects: 20
Study: 27284581

Group type: EXPERIMENTAL
Intervention: Ultracaine DS Forte (treatment group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ultracaine DS (control group)
Number of subjects: 50
Study: 23881570

Group type: EXPERIMENTAL
Intervention: Group 2 (20 words once)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Group 3 (20 words three times)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Group 1 (2 words once)
Number of subjects: 3
Study: 22736126

Group type: EXPERIMENTAL
Intervention: Nasogastric tube
Number of subjects: 174

Group type: COMPARATOR
Intervention: Non-nasogastric tube
Number of subjects: 174
Study: 19864082

Group type: EXPERIMENTAL
Intervention: Androgen suppression therapy (AST) plus radiation therapy (RT)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 206
Study: 18378136

Group type: EXPERIMENTAL
Intervention: Pelvic radiation (51 Gy in 28 fractions over 5 weeks)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 224
Study: 15653378

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day for 6 months
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 10
Study: 12716753

Group type: EXPERIMENTAL
Intervention: CR-LIPE diet
Number of subjects: 191

Group type: COMPARATOR
Intervention: Standard protein restriction
Number of subjects: 191
Study: 10507820

Group type: EXPERIMENTAL
Intervention: Laparoscopic catheter insertion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional catheter insertion
Number of subjects: 50